Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020

Eurosurveillance - Tập 25 Số 28 - 2020
Heli Harvala1, Jennifer Mehew2, Matthew Robb2, Samreen Ijaz3, Steve Dicks1,3, Monika Patel4, Nicholas A. Watkins5, Peter Simmonds6, Tim Brooks7, Rachel Johnson2, Robin Gopal4, David J. Roberts8,9, Maria Zambon3
1Microbiology Services, NHS Blood and Transplant, London, United Kingdom
2Statistics and Clinical Studies, NHS Blood and Transplant, Bristol, United Kingdom
3Virology Reference Department, National Infection Service, Public Health England, Colindale Avenue, London, United Kingdom
4High Containment Microbiology, National Infection Service, Public Health England, Colindale Avenue, London, United Kingdom
5NHS Blood and Transplant, Cambridge, United Kingdom
6Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
7Rare & Imported Pathogens Laboratory, Public Health England, Porton Down, United Kingdom
8NHS Blood and Transplant, Oxford, John Radcliffe Hospital, Oxford, United Kingdom
9Radcliffe Department of Medicine and BRC Haematology Theme, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom

Tóm tắt

Serological reactivity was analysed in plasma from 436 individuals with a history of disease compatible with COVID-19, including 256 who had been laboratory-confirmed with SARS-CoV-2 infection. Over 99% of laboratory-confirmed cases developed a measurable antibody response (254/256) and 88% harboured neutralising antibodies (226/256). Antibody levels declined over 3 months following diagnosis, emphasising the importance of the timing of convalescent plasma collections. Binding antibody measurements can inform selection of convalescent plasma donors with high neutralising antibody levels.

Từ khóa


Tài liệu tham khảo

World Health Organization (WHO). Coronavirus disease (COVID-19) pandemic. [Accessed 10 Jun 2020]. Geneva: WHO. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019

2020, The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2., Nat Microbiol, 5, 536, 10.1038/s41564-020-0695-z

An EU programme of COVID-19 convalescent plasma collection and transfusion Guidance on collection, testing, processing, storage, distribution and monitored use. [Accessed 12 Jun 2020]. Available from: https://ec.europa.eu/health/sites/health/files/blood_tissues_organs/docs/guidance_plasma_covid19_en.pdf

Recommendations for Investigations COVID-19 Convalescent Plasma recommendation. 1 May 2020. [Accessed 12 Jun 2020]. Available from: https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma

Duan, 2020, Effectiveness of convalescent plasma therapy in severe COVID-19 patients., Proc Natl Acad Sci USA, 117, 9490, 10.1073/pnas.2004168117

Shen, 2020, Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma., JAMA, 323, 1582, 10.1001/jama.2020.4783

Rojas, 2020, Convalescent plasma in Covid-19: Possible mechanisms of action., Autoimmun Rev, 19, 10.1016/j.autrev.2020.102554

Long, 2020, Antibody responses to SARS-CoV-2 in patients with COVID-19., Nat Med, 26, 845, 10.1038/s41591-020-0897-1

Guo, 2020, Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)., Clin Infect Dis, 10.1093/cid/ciaa310

Zhao, 2020, Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019., Clin Infect Dis, 10.1093/cid/ciaa344

Wu, 2020, Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications, 10.2139/ssrn.3566211

Wang X, Guo X, Xin Q, Pan Y, Li j, Chu Y, et al. Neutralising antibody responses to SARS-CoV-2 in COVID-19 inpatients and convalescent patients. MedRxiv. 2020. Available from: https://www.medrxiv.org/content/10.1101/2020.04.15.20065623v3

Harvala, 2020, Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels, 10.1101/2020.05.20.20091694

Roberts, 2020, Convalescent plasma for COVID-19: Back to the future., Transfus Med, 30, 174, 10.1111/tme.12700

Agnihothram, 2014, Evaluation of serologic and antigenic relationships between middle eastern respiratory syndrome coronavirus and other coronaviruses to develop vaccine platforms for the rapid response to emerging coronaviruses., J Infect Dis, 209, 995, 10.1093/infdis/jit609

Jääskeläinen, 2020, Evaluation of commercial and automated SARS-CoV-2 IgG and IgA ELISAs using coronavirus disease (COVID-19) patient samples., Euro Surveill, 25, 10.2807/1560-7917.ES.2020.25.18.2000603

Brochot, 2020, Anti-spike, anti-nucleocapsid and neutralising antibodies in SARS-CoV-2 inpatients and asymptomatic carriers

Lassaunière, 2020, Evaluation of nine commercial SARS-CoV-2 immunoassays., 10.1101/2020.04.09.20056325

Caini, 2020, Meta-analysis of diagnostic performance of serological tests for SARS-CoV-2 antibodies up to 25 April 2020 and public health implications., Euro Surveill, 25, 10.2807/1560-7917.ES.2020.25.23.2000980

Okba, 2020, Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients., Emerg Infect Dis, 26, 1478, 10.3201/eid2607.200841

Thông tin
Thông tin xuất bản

Eurosurveillance

Tập 25 Số 28

Thông tin tác giả